viewImugene Ltd

Imugene well-funded to progress clinical milestones

The company is currently fully funded in supporting all clinical research programs.

australian bank notes
The company’s vaccines are targeting the gastric and lung cancer market

Imugene Ltd (ASX:IMU) finished the March quarter with $21 million in the bank, positioning it well as it progresses its commercial and clinical milestones over the coming quarters.

The company has a strong pipeline of cancer vaccines in development.

In March 2019, the company dosed its first patient with its HER-Vaxx (IMU131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

This marked an important milestone for the company in advancing its Phase II trials.

Additionally, Imugene presented the Phase 1b study results of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) meeting in April 2019.

READ: Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx

Furthermore, positive new data findings from the active immunisation studies for KEY-Vaxx earlier this year provided proof of concept and validation for the human PD-1 cancer vaccine.

The FDA meeting in February 2019 was productive and provided Imugene with a clear roadmap for a successful IND submission and subsequent clinical development of KEY-Vaxx.

READ: Imugene gets development roadmap for cancer vaccine from FDA meeting

Quick facts: Imugene Ltd

Price: 0.035 AUD

Market: ASX
Market Cap: $154.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read